EXEL Stelios Papadopoulos sells $4.4M worth of shares
Nov 14, 2025, 5:34 AM
0.00%
What does EXEL do
Exelixis, an oncology company based in Alameda, California, focuses on developing treatments for difficult-to-treat cancers, with four marketed products including cabozantinib for various cancers. Founded in 2000, it employs 1,310 people.
Stelios Papadopoulos sold 100,000 shares of EXEL on 12 November at $43.55 per share, worth a total of $4.4M. They now own 1,189,228 EXEL shares, or a 8% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.